Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm

(1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients. (2) Methods: In this single-center, randomized, double-blind, placebo-controlled trial (N...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lesley E. Jackson, Nitasha Khullar, Timothy Beukelman, Chris Chapleau, Abhishek Kamath, Randy Q. Cron, Walter Winn Chatham
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-09-01
coleção:	Viruses
Assuntos:	SARS-CoV-2 antiviral treatment anakinra
Acesso em linha:	https://www.mdpi.com/1999-4915/15/10/2036
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!